RT Journal Article
SR Electronic
T1 Development and potential usefulness of the COVID-19 Ag Respi-Strip® diagnostic assay in a pandemic context
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.24.20077776
DO 10.1101/2020.04.24.20077776
A1 Mertens, Pascal
A1 De Vos, Nathalie
A1 Martiny, Delphine
A1 Jassoy, Christian
A1 Mirazimi, Ali
A1 Cuypers, Lize
A1 Van Den Wijngaert, Sigi
A1 Monteil, Vanessa
A1 Melin, Pierrette
A1 Stoffels, Karolien
A1 Yin, Nicolas
A1 Mileto, Davide
A1 Delaunoy, Sabrina
A1 Magein, Henri
A1 Lagrou, Katrien
A1 Bouzet, Justine
A1 Serrano, Gabriela
A1 Wautier, Magali
A1 Leclipteux, Thierry
A1 Van Ranst, Marc
A1 Vandenberg, Olivier
A1 LHUB-ULB SARS-COV-2 working diagnostic group
A1 Gulbis, Béatrice
A1 Brancart, Françoise
A1 Bry, François
A1 Cantinieaux, Brigitte
A1 Corazza, Francis
A1 Cotton, Fréderic
A1 Dresselhuis, Maud
A1 Mahadeb, Bhavna
A1 Roels, Olivier
A1 Vanderlinden, Jacques
YR 2020
UL http://medrxiv.org/content/early/2020/04/29/2020.04.24.20077776.abstract
AB Introduction COVID-19 Ag Respi-Strip, an immunochromatographic (ICT) assay for the rapid detection of SARS-CoV-2 antigen on nasopharyngeal specimen, has been developed to identify positive COVID-19 patients allowing prompt clinical and quarantine decisions. In this Original Research article, we describe the conception, the analytical and clinical performances as well as the risk management of implementing the COVID-19 Ag Respi-Strip in a diagnostic decision algorithm.Materials and Methods Development of the COVID-19 Ag Respi-Strip resulted in a ready- to-use ICT assay based on a membrane technology with colloidal gold nanoparticles using monoclonal antibodies directed against the SARS-CoV and SARS-CoV-2 highly conserved nucleoprotein antigen. Four hundred observations were recorded for the analytical performance study and thirty tests were analysed for the cross-reactivity study. The clinical performance study was performed in a retrospective multi-centric evaluation on aliquots of 328 nasopharyngeal samples. COVID-19 Ag Respi-Strip results were compared with qRT-PCR as golden standard for COVID-19 diagnostics.Results In the analytical performance study, the reproducibility showed a between-observer disagreement of 1.7%, a robustness of 98%, an overall satisfying user friendliness and no cross-reactivity with other virus-infected nasopharyngeal samples. In the clinical performance study performed in three different clinical laboratories we found an overall sensitivity and specificity of 57.6% and 99.5% respectively with an accuracy of 82.6%. The cut-off of the assay was found at Ct<22. User-friendliness analysis and risk management assessment through Ishikawa diagram demonstrate that COVID-19 Ag Respi-Strip may be implemented in clinical laboratories according to biosafety recommendations.Conclusion The COVID-19 Ag Respi-Strip represents a promising rapid SARS-CoV-2 antigen assay for the first-line diagnosis of COVID-19 in 15 minutes. Its role in the proposed diagnostic algorithm is complementary to the currently-used molecular techniques.Competing Interest StatementTwo parties have merged their expertise within this article with the intention of delivering a publication in the interest of the public health system: On the one hand, the IVD medical device has been developed by the investigator Pascal Mertens, Henri Magein, and Justine Bouzet working for Coris BioConcept and therefore considered a scientific investigators with potential conflict of interest even they don’t have any share in this company. Thierry Leclipteux was also involved in the development of this test and as CEO of Coris Bioconcept he has a potential conflict of interest. On the other hand, the validation as described in the analytical performance study, the clinical performance study and the risk management have been done completely independent from Coris BioConcept, without any conflict of financial interest. All scientific investigators that are external to Coris BioConcept declare having no conflict of interest. Coris BioConcept has offered the reagents for validation and after CE-certification, some kits for diagnosing the homeless people suspected with COVID-19 in Brussels.Funding StatementNo fundingAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available